Walk to Defeat ALS marks 25 years of fundraising event in US

Walk to Defeat ALS marks 25 years of fundraising event in US

The ALS Association’s Walk to Defeat ALS fundraising event this year is marking 25 years of bringing together people with amyotrophic lateral sclerosis (ALS) and their families to offer support and raise funds for advancing research and improving care for those living with the disease. With a total…

Voyager Therapeutics reassesses SOD1-ALS gene therapy program

Voyager Therapeutics will reassess its gene therapy program for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene after its original candidate, VY9323, was found to have toxic effects in nonhuman primate studies. The company believes the problem lies with the therapy’s payload and not the viral carrier…